Program
BI 3000202
A development code.
Its studies are mostly in Lupus Erythematosus, Systemic, led by Boehringer Ingelheim.
Furthest: phase 2, since Feb 9, 20267 company-led studies, 2 open or runningNext primary completion: Feb 21, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 72 open or running | phase 2since Feb 9, 2026 | Jul 7, 2023 | Feb 21, 2027phase 1 · NCT07774325 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2023First study: phase 1 study in HealthyFirst studyNCT05945888 · 68 enrolled · Germany
- Mar 18, 2024Phase 1 study in HealthyNCT06327256 · 40 enrolled · Belgium
- Oct 9, 2025Phase 1 study in HealthyNCT07215260 · 14 enrolled · Germany
- Nov 27, 2025Phase 1 study in HealthyNCT07273474 · 12 enrolled · Netherlands
- Feb 9, 2026Phase 2 study in Lupus Erythematosus, SystemicPhase 2 reachedNCT07409181 · 405 planned · United States, Argentina, Australia and more
- Mar 17, 2026Phase 1 study in HealthyNCT07486102 · 34 enrolled · United States
- Aug 17, 2026Phase 1 study in HealthyNCT07774325 · 10 enrolled · Germany
- Nov 13, 2026Primary completion moved from 2026-12-06 to 2029-12-10Date moved laterphase 1 · +36 months · NCT06878365
Ahead
- Feb 21, 2027Primary completion: phase 1 study in HealthyNCT07774325
- Feb 4, 2029Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07409181
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07774325Healthy · Germany | 1 | Active, not recruiting | Feb 21, 2027 | 10 |
| NCT07486102Healthy · United States | 1 | Completed | Oct 30, 2026 | 34 |
| NCT07409181Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Recruiting | Feb 4, 2029 | 405 |
| NCT07273474Healthy · Netherlands | 1 | Completed | Mar 5, 2026 | 12 |
| NCT07215260Healthy · Germany | 1 | Completed | Dec 7, 2025 | 14 |
| NCT06327256Healthy · Belgium | 1 | Completed | Sep 27, 2024 | 40 |
| NCT05945888Healthy · Germany | 1 | Completed | Nov 13, 2023 | 68 |
How it is read
Names in the registry
- “BI 3000202”, 7 entries
Codes read as this program: BI3000202.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.